New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 39 years old, depending on the cancer type and trial phase.
- You must have Wilms tumor, desmoplastic small round cell tumor (DSRCT), or osteosarcoma that has returned or not responded to treatment.
- Your tumor must be measurable on scans, and you must have had at least standard initial therapy.
- You must have recovered from side effects of prior treatments, and meet certain blood and organ function levels.
- You cannot have had prior HER2-directed therapies like trastuzumab or certain other targeted drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
This trial tests a new type of immunotherapy that targets a specific genetic change in Ewing sarcoma and a related rare tumor called DSRCT. It may be an option for patients whose cancer has come back, spread, or is very high-risk after standard chemotherapy.
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
This trial tests two targeted drugs, selumetinib and DS-8201a (trastuzumab deruxtecan), for advanced pancreatic cancer that has spread or cannot be removed. The combination may help people whose tumors have specific markers (KRAS mutation and HER2 positivity).
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Hear when a new Desmoplastic Small Round Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.